Listed

ImmunityBio, Inc.: Form 10-Q for the period ended Sep 30, 2019

Filed with the SEC on Nov 5, 2019 and accepted by EDGAR at Nov 5, 2019, 16:06 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2019-07-01 to 2019-09-30$12.0kus-gaap:Revenues
Revenue9 months2019-01-01 to 2019-09-30$34.0kus-gaap:Revenues
Research and development3 months2019-07-01 to 2019-09-30$12.1mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2019-01-01 to 2019-09-30$37.8mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2019-07-01 to 2019-09-30$4.0mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2019-01-01 to 2019-09-30$13.9mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2019-07-01 to 2019-09-30−$16.1mus-gaap:OperatingIncomeLoss
Operating income9 months2019-01-01 to 2019-09-30−$51.7mus-gaap:OperatingIncomeLoss
Income tax3 months2019-07-01 to 2019-09-30$0us-gaap:IncomeTaxExpenseBenefit
Income tax9 months2019-01-01 to 2019-09-30−$34.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2019-07-01 to 2019-09-30−$15.6mus-gaap:NetIncomeLoss
Net income9 months2019-01-01 to 2019-09-30−$50.1mus-gaap:NetIncomeLoss
Diluted EPS3 months2019-07-01 to 2019-09-30−$0.16us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2019-01-01 to 2019-09-30−$0.54us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2019-01-01 to 2019-09-30−$46.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2019-01-01 to 2019-09-30$3.5mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases9 months2019-01-01 to 2019-09-30$501.0kus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2019-09-30$18.3mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-09-30$71.6mus-gaap:AssetsCurrent
Total assetsAt period end2019-09-30$160.2mus-gaap:Assets
Current liabilitiesAt period end2019-09-30$12.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-09-30$24.3mus-gaap:Liabilities
Shareholders' equityAt period end2019-09-30$136.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001564590-19-040363. Last ingested by Listed: Nov 9, 2026, 17:45 ET. Listed shows no prices and gives no investment advice.